Preconditioned or IL4-Secreting Mesenchymal Stem Cells Enhanced Osteogenesis at Different Stages
Publication: Tissue Engineering Part A
Volume 25, Issue Number 15-16
Abstract
Chronic inflammation-associated bone diseases involve continuous destruction and impaired regeneration of bone. Mesenchymal stem cell (MSC)-based therapy has great potential to modulate inflammatory responses and enhance tissue regeneration. We previously showed that lipopolysaccharide (LPS) plus tumor necrosis factor alpha (TNFα)-preconditioned MSCs or genetically modified inflammation-sensing (driven by nuclear factor kappa-light-chain-enhancer of activated B cells [NFκB] activation) IL4-secreting MSCs enhanced immunomodulation of macrophages to the more desired tissue repaired M2 type. In the current study, the paracrine regulation of therapeutic MSCs on the proinflammatory response and osteogenesis of macrophage–MSC cocultures (representing endogenous cells) was examined using an in vitro transwell system. In the cocultures, IL4-secreting MSCs decreased TNFα and inducible nitric oxide synthase expression, and increased Arginase 1 and CD206 expression in the presence of LPS-contaminated polyethylene particles. The preconditioned MSCs decreased TNFα and CD206 expression in the bottom MSC–macrophage cocultures in the presence of contaminated particles. In osteogenesis assays, IL4-secreting MSCs decreased alkaline phosphatase (ALP) expression, but increased Alizarin Red staining in the presence of contaminated particles. The preconditioned MSCs increased ALP and osteocalcin expression, and had no significant effect on Alizarin Red staining. These results suggest that potential treatments using preconditioned MSCs at an earlier stage, or IL4-secreting MSCs at a later stage could enhance bone regeneration in inflammatory conditions, including periprosthetic osteolysis.
Impact Statement
Pathogen-associated molecular patterns, damage-associated molecular patterns, and other noxious stimuli activate macrophages to induce the proinflammatory responses. Modulation of inflammatory macrophages (M1) into an anti-inflammatory tissue repair macrophage (M2) phenotype at the appropriate time optimizes bone remodeling and regeneration. Simulating the proinflammatory stimuli by using preconditioned mesenchymal stem cells (MSCs) at an earlier stage, and alleviate the inflammation by using IL4-secreting MSCs at a later stage could further optimize bone regeneration in chronic inflammatory conditions, including periprosthetic osteolysis.
Get full access to this article
View all available purchase options and get full access to this article.
References
1. Goodman S.B. Wear particles, periprosthetic osteolysis and the immune system. Biomaterials 28, 5044, 2007.
2. Ingham E., and Fisher J. The role of macrophages in osteolysis of total joint replacement. Biomaterials 26, 1271, 2005.
3. Loi F., Cordova L.A., Pajarinen J., Lin T.H., Yao Z., and Goodman S.B. Inflammation, fracture and bone repair. Bone 86, 119, 2016.
4. Squillaro T., Peluso G., and Galderisi U. Clinical trials with mesenchymal stem cells: an update. Cell Transplant 25, 829, 2016.
5. Loi F., Cordova L.A., Zhang R., et al. The effects of immunomodulation by macrophage subsets on osteogenesis in vitro. Stem Cell Res Ther 7, 15, 2016.
6. Lu L.Y., Loi F., Nathan K., et al. Pro-inflammatory M1 macrophages promote osteogenesis by mesenchymal stem cells via the COX-2-prostaglandin E2 pathway. J Orthop Res 35, 2378, 2017.
7. Vi L., Baht G.S., Whetstone H., et al. Macrophages promote osteoblastic differentiation in-vivo: implications in fracture repair and bone homeostasis. J Bone Miner Res 30, 1090, 2015.
8. Nathan K., Lu L., Pajarinen J., et al. Temporal modulation of macrophage polarization enhances osteogenesis in primary mesenchymal stem cells. ORS Conference Abstract 0765, 2017.
9. Lin T., Pajarinen J., Nabeshima A., et al. Preconditioning of murine mesenchymal stem cells synergistically enhanced immunomodulation and osteogenesis. Stem Cell Res Ther 8, 277, 2017.
10. Lin T., Pajarinen J., Nabeshima A., et al. Establishment of NF-kappaB sensing and interleukin-4 secreting mesenchymal stromal cells as an “on-demand” drug delivery system to modulate inflammation. Cytotherapy 19, 1025, 2017.
11. Lin T., Kohno Y., Huang J.F., et al. NFkappaB sensing IL-4 secreting mesenchymal stem cells mitigate the proinflammatory response of macrophages exposed to polyethylene wear particles. J Biomed Mater Res A 106, 2744, 2018.
12. Lin T.H., Sato T., Barcay K.R., et al. NF-kappaB decoy oligodeoxynucleotide enhanced osteogenesis in mesenchymal stem cells exposed to polyethylene particle. Tissue Eng Part A 21, 875, 2014.
13. Lu L.Y., Loi F., Nathan K., et al. Pro-inflammatory M1 macrophages promote osteogenesis by mesenchymal stem cells via the COX-2-prostaglandin E2 pathway. J Orthop Res 35, 2378, 2017.
14. Ricciotti E., and FitzGerald G.A. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol 31, 986, 2011.
15. Nemeth K., Leelahavanichkul A., Yuen P.S., et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15, 42, 2009.
16. Ylostalo J.H., Bartosh T.J., Coble K., and Prockop D.J. Human mesenchymal stem/stromal cells cultured as spheroids are self-activated to produce prostaglandin E2 that directs stimulated macrophages into an anti-inflammatory phenotype. Stem Cells 30, 2283, 2012.
17. Hart P.H., Cooper R.L., and Finlay-Jones J.J. IL-4 suppresses IL-1 beta, TNF-alpha and PGE2 production by human peritoneal macrophages. Immunology 72, 344, 1991.
18. Shay A.E., Diwakar B.T., Guan B.J., Narayan V., Urban J.F. Jr., and Prabhu K.S. IL-4 up-regulates cyclooxygenase-1 expression in macrophages. J Biol Chem 292, 14544, 2017.
19. Knight M.N., and Hankenson K.D. Mesenchymal stem cells in bone regeneration. Adv Wound Care (New Rochelle) 2, 306, 2013.
20. Dahlin R.L., Kinard L.A., Lam J., et al. Articular chondrocytes and mesenchymal stem cells seeded on biodegradable scaffolds for the repair of cartilage in a rat osteochondral defect model. Biomaterials 35, 7460, 2014.
Information & Authors
Information
Published In
Tissue Engineering Part A
Volume 25 • Issue Number 15-16 • August 2019
Pages: 1096 - 1103
PubMed: 30652628
Copyright
Copyright 2019, Mary Ann Liebert, Inc., publishers.
History
Published online: 5 August 2019
Published in print: August 2019
Published ahead of print: 27 March 2019
Published ahead of production: 17 January 2019
Accepted: 8 November 2018
Received: 9 October 2018
Topics
Authors
Disclosure Statement
The authors have no conflict of interest to declare.
Metrics & Citations
Metrics
Citations
Export Citation
Export citation
Select the format you want to export the citations of this publication.
View Options
Get Access
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.⚠ Society Access
If you are a member of a society that has access to this content please log in via your society website and then return to this publication.